Onkologie. 2010:4(3):149-153
Examination methods and prognostic factors in Hodgkin lymphoma
- Oddělení klinické hematologie, FN Královské Vinohrady, Praha
The correct diagnosis, initial evaluation of clinical stage and prognostic factors are basic tools for treatment tailoring in patients with
Hodgkin lymphoma (HL). The aim is to achieve the best tumor control with minimal adverse effects, especially late effects of therapy.
Computed tomography (CT) remains the standard imaging method in initial staging before therapy. Positron emission tomography
(PET) is a new method for a more precise initial staging and it is an important tool for evaluation of response early after two cycles of
therapy and at the end of first-line treatment. Risk factors in early stages of HL include: massive mediastinal tumor, extranodal involvement,
high erythrocyte sedimentation rate and number of involved lymph node localizations. The international prognostic score (IPS)
is used for evaluation of prognosis in advanced stages of HL, but its significance is overshadowed by PET performed after two cycles of
chemotherapy with high negative and positive predictive value.
Keywords: Hodgkin lymphoma, imaging methods, prognostic factors
Published: July 1, 2010 Show citation
References
- Brice P, Colin P, Berger F, et al. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy. Cancer 2001; 92: 453-459.
Go to original source... - Lister TA, Crowther D, Sutclife SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636. Go to original source...
Go to PubMed... - Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extendedfield radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-502. Go to original source... Go to PubMed...
- Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273. Go to PubMed...
- Isasi CR, Lu P, Balufox MD, et al. A metaanalysis of 18F-2deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymhoma. Cancer 2005; 104: 1066-1074. Go to original source... Go to PubMed...
- Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. Go to original source... Go to PubMed...
- Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007; 25: 571-578. Go to original source... Go to PubMed...
- Mendenhall NP, Cantor AB, Barre DM, et al. The role of prognostic factors in treatment selection for early-stage Hodgkin´s disease. Am J Clin Oncol 1994; 17: 189-195. Go to original source... Go to PubMed...
- Specht L, Nordentoft AM, Cold S, et al. Tumor burden as the most important prognostic factor in early-stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 1988; 61: 1719-1727. Go to original source...
- Noordijk EM, Carde P, Mandard AM, et al. preliminary results of the EORTC-GPMC controlled trial H7 in early-stage Hodgkin´s disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie Curie. Ann Oncol. 1994; Suppl 2: 107-112. Go to original source... Go to PubMed...
- Meyer RM, Gospodarowitz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 4634-4642. Go to original source... Go to PubMed...
- Low SE, Horsman JM, Walters SJ, et al. Risk-adjusted prognostic models for Hodgkin´s disease (HD) and grade II nonHodgkin´s lymphoma (NHLII): validation on 6728 British National Lymphoma Investigation patients. Br. J. Haematol. 2003; 120: 277-280. Go to original source... Go to PubMed...
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin´s disease. International Prognostic Factors Project on Advanced Hodgkin´s Disease. N Engl J Med 1998; 339: 1506-1514. Go to original source... Go to PubMed...
- Specht L, Nissen NI. Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 1988; 41: 359-367. Go to original source... Go to PubMed...
- Strauss DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternative potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 8: 1173-1186. Go to original source... Go to PubMed...
- Wagstaff J, Steward W, Jones M, et al. Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP. Hematol Oncol 1986; 4: 135-147. Go to original source... Go to PubMed...
- Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 12995-1306. Go to original source... Go to PubMed...
- Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59. Go to original source... Go to PubMed...
- Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007; 25: 3746-3752. Go to original source... Go to PubMed...